The 2024 US Medical Eligibility Criteria for Contraceptive Use (US MEC) comprises recommendations for the use of specific contraceptive methods by persons who have certain characteristics or medical conditions. These recommendations for health care providers were updated by CDC after review of the scientific evidence and a meeting with national ... Read more >

The 2024 US Selected Practice Recommendations for Contraceptive Use (US SPR) addresses a selected group of common, yet sometimes complex, issues regarding initiation and use of specific contraceptive methods. These recommendations for health care providers were updated by CDC after review of the scientific evidence and a meeting with national ... Read more >

On March 4, 2024, the first daily over-the-counter oral contraceptive pill became available in the United States. This progestin-only pill (POP) is approved without a prescription for adolescents and adults to prevent pregnancy. The FDA did not approve this POP for menstrual suppression or other noncontraceptive indications. For both adults ... Read more >

Mifepristone approval by the United States (US) Food and Drug Administration in 2000 revolutionized abortion care in this country. In the aftermath of the US Supreme Court’s decision in Dobbs v. Jackson Women’s Health Organization which eliminated federal constitutional protections for abortion, the accessibility and availability of mifepristone are under ... Read more >

On January 3, 2023, updates to the U.S. Food and Drug Administration (FDA) risk evaluation and mitigation strategy (REMS) for mifepristone for reproductive health indications went into effect. The FDA has permanently removed the in-person dispensing requirement and added a new pharmacy certification process, which will enable retail pharmacies that ... Read more >